SCHEMBL2124845

SCHEMBL2124845

c1nc2c(cc1N1CCOCC1)NCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.39
CHRNB2 P17787 3/20 0.38
CHRNA4 P43681 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPT P10636 2/20 0.38
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 2/20 0.37
CNR2 P34972 1/20 0.37
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
RECQL P46063 1/20 0.36
KMT2A Q03164 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
PIK3CD O00329 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2233765 0.78 CHRNB2 (0.38) CHRNB2CHRNA4MAPTKDM4E
SCHEMBL2123342 0.77 POLB (0.36) POLBCHRNB2CHRNA4L3MBTL1MAPT
SCHEMBL2123191 0.71 PIK3CA (0.41) PIK3CDPIK3CAPIK3CB
SCHEMBL24783546 0.70 ALDH1A1 (0.46) MAPTALDH1A1SMN1; SMN2LMNAKDM4E
SCHEMBL30226755 0.70 ALDH1A1 (0.46) MAPTALDH1A1SMN1; SMN2LMNAKDM4E
SCHEMBL2123688 0.70 PIK3CA (0.40) POLBCHRNB2CHRNA4PIK3CDPIK3CA
SCHEMBL31244824 0.68 HTR2C (0.42) CHRNB2CHRNA4PIK3CDPIK3CAPIK3CB
SCHEMBL12205229 0.68 LRRK2 (0.51) POLBCHRNB2CHRNA4L3MBTL1MAPT
SCHEMBL2123764 0.68 PSMD14 (0.43) IRAK4MAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL20595611 0.67 DYRK1A (0.35) MAPTALDH1A1SMN1; SMN2LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765940-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-07-01 US disclosed
US-20120094972-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094972-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 POLB 1724/4885IRAK4 224/4885CHRNB2 4119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.